查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球CAR T细胞疗法市场
市场调查报告书
商品编码
1296899

2023-2030年全球CAR T细胞疗法市场

Global CAR T Cell Therapy Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

CAR T细胞疗法治疗淋巴瘤和其他血癌的早期结果是很有希望的。多名标准治疗失败或血癌复发的患者通过CAR T细胞疗法取得了完全成功。因此，美国食品和药物管理局正专注于细胞和基因疗法的审批。几种CAR T细胞疗法正处于临床阶段，用于治疗乳腺癌、结直肠癌和血癌。这些新型疗法的推出将可能为市场的增长提供机会。

分段展望

全球CAR T细胞疗法市场根据应用和目标抗原进行细分。基于应用，市场被分为非霍奇金淋巴瘤、急性淋巴细胞白血病和其他。基于目标抗原，市场被分为CD19、CD22和其他。

CD19靶抗原在全球CAR T细胞治疗市场上占有最大份额

目录

第一章：报告摘要

  • 研究方法和工具
  • 市场细分
    • 按领域划分
    • 按地理区域分类

第二章：市场概述和洞察力

  • 报告的范围
  • 分析师的洞察力和当前的市场趋势
    • 主要发现
    • 建议
    • 总结

第三章：竞争格局

  • 主要公司分析
  • Novartis International AG
    • 概述
    • 财务分析
    • SWOT分析
    • 近期发展情况
  • Gilead Sciences, Inc.
    • 概况
    • 财务分析
    • SWOT分析
    • 近期发展情况
  • Pfizer, Inc.
    • 进展概况
    • 财务分析
    • SWOT分析
    • 近期发展情况
  • Bristol-Myers Squibb Co.
    • 进展概况
    • 财务分析
    • SWOT分析
    • 近期发展情况
  • Takeda Pharmaceutical Co. Ltd.
    • 进展概况
    • 财务分析
    • SWOT分析
    • 近期发展情况

第四章：市场细分

  • 全球CAR T细胞疗法市场的应用
    • 非霍奇金淋巴瘤
    • 急性淋巴细胞白血病
    • 其他（多发性骨髓瘤、霍奇金淋巴瘤和乳腺癌）。
  • 全球CAR T细胞疗法市场按目标抗原分类
    • CD19
    • CD22
    • 其他（CD123、CD33和BCMA）。

第五章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 亚太其他地区
  • 世界其他地区

第六章：公司简介

  • Amgen Inc.
  • Autolus Therapeutics plc
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Co.
  • CARsgen Therapeutics Co., Ltd.
  • Cellectis SA
  • Celyad SA
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Janssen Global Services, LLC (a Subsidiary of Johnson & Johnson)
  • LesLaboratoiresServier, SAS
  • Mustang Bio
  • Nanjing Legend Biotechnology Co., Ltd.
  • Noile-Immune Biotech Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Precigen, Inc.
  • Sangamo Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • Takeda Pharmaceutical Co. Ltd.
Product Code: OMR2027374

Global CAR T cell therapy market is estimated to grow at a CAGR of 12.0% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer across the globe and rising FDA approvals for cell and gene therapy. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Around 43.8 million people were living with cancer in 2018 and were diagnosed within the last 5 years. This rising prevalence of cancer is attributed to the development of CAR T cell therapy. It is a form of immunotherapy that utilizes specially altered T cells, a part of the immune system to attack cancer. There are currently two CAR T cell therapies approved for the treatment of cancer, which include Yescarta and Kymriah. Yescarta was approved by the US FDA in October 2017, for the treatment of diffuse large B-cell lymphoma (DLBCL). Kymriah was approved by the US FDA in May 2018, for the treatment of adults with certain kinds of non-Hodgkin lymphoma. Kymriah is also approved for the treatment of children and young adults with leukemia. In clinical trials, more than 80% of young adults and children treated with Kymriah achieved cancer remission.

Early results of CAR T-cell therapy to treat lymphoma and other blood cancers are promising. Multiple patients with failed standard treatments or whose blood cancers returned achieved complete success with CAR T cell therapy. As a result, the US FDA is focusing on the approvals of cell and gene therapies. Several CAR T cell therapies are in clinical phases for the treatment of breast cancer, colorectal cancer, and blood cancer. The launch of these novel therapies will likely offer an opportunity for the growth of the market.

Segmental Outlook

The global CAR T cell therapy market is segmented based on application and target antigen. Based on application, the market is classified into non-Hodgkin lymphoma, acute lymphocytic leukemia, and others. Based on target antigen, the market is classified into CD19, CD22, and others.

CD19 target antigen held the largest share in the global CAR T cell therapy market

Among target antigens, CD19 has witnessed considerable growth in 2018. Both CAR-T therapies, including Yescarta and Kymriah available in the market target CD19 for the treatment of several forms of cancers affecting B cells, including leukemia and lymphoma. The advantages related to these CAR-T cell therapies have been shown in clinical trials that have led researchers and biotechnology firms to conduct operations in the CD19 target space. For instance, in November 2019, the University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Co. Ltd. declared an exclusive license agreement and research agreement for the development of blood-derived CAR-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, to treat B-cell malignancies and other cancers. In terms of the agreement, Takeda will get access to the CAR NK platform of MD Anderson and the exclusive rights for the development and commercialization of up to four programs, such as aB-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and CD19-targeted CAR NK-cell therapy. The emerging clinical trials for CD19 targeted antigen CAR T cell therapy is providing enormous opportunity for the growth of the market.

Regional Outlook

The global CAR T cell therapy market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America held the largest share in the market owing to the significant prevalence of cancer and significant share in life science research in the region. The presence of major players, including Gilead Sciences, Inc., Pfizer, Inc., and Bristol-Myers Squibb Co. are offering scope for market growth in the region. Increasing US FDA approvals for cell therapy owing to its effectiveness in clinical trials is further providing enormous opportunities for the growth of the market in the region.

Market Players Outlook

The major players in the global CAR T cell therapy market include Novartis International AG, Gilead Sciences, Inc., Pfizer, Inc., Bristol-Myers Squibb Co., and Takeda Pharmaceutical Co. Ltd. These companies are significantly focusing on the development of cell-based therapies as it targets the tumors with more precision, as compared to chemo and radiation therapy. Several partnerships among companies have been reported for the development and commercialization of CAR T cell therapies. For instance, in May 2019, Kite, a Gilead Co., and Humanigen, Inc. declared a clinical partnership for conducting a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This study aims to define the effect of lenzilumab on Yescarta safety. Kite will be responsible to conduct this study and act as a sponsor for the study.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Novartis International AG
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Gilead Sciences, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Bristol-Myers Squibb Co.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Takeda Pharmaceutical Co. Ltd.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments

4. Market Segmentation

  • 4.1. Global CAR T Cell Therapy Market by Application
    • 4.1.1. Non-Hodgkin Lymphoma
    • 4.1.2. Acute Lymphocytic Leukemia
    • 4.1.3. Others (Multiple Myeloma, Hodgkin Lymphoma, and Breast Cancer)
  • 4.2. Global CAR T Cell Therapy Market by Target Antigen
    • 4.2.1. CD19
    • 4.2.2. CD22
    • 4.2.3. Others (CD123, CD33, and BCMA)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Amgen Inc.
  • 6.2. Autolus Therapeutics plc
  • 6.3. Bluebird Bio, Inc.
  • 6.4. Bristol-Myers Squibb Co.
  • 6.5. CARsgen Therapeutics Co., Ltd.
  • 6.6. Cellectis SA
  • 6.7. Celyad SA
  • 6.8. Gilead Sciences, Inc.
  • 6.9. Intellia Therapeutics, Inc.
  • 6.10. Janssen Global Services, LLC (a Subsidiary of Johnson & Johnson)
  • 6.11. LesLaboratoiresServier, SAS
  • 6.12. Mustang Bio
  • 6.13. Nanjing Legend Biotechnology Co., Ltd.
  • 6.14. Noile-Immune Biotech Inc.
  • 6.15. Novartis International AG
  • 6.16. Pfizer, Inc.
  • 6.17. Precigen, Inc.
  • 6.18. Sangamo Therapeutics, Inc.
  • 6.19. Sorrento Therapeutics, Inc.
  • 6.20. Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES

  • 1. GLOBAL CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
  • 2. GLOBAL CAR T CELL THERAPY IN NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
  • 3. GLOBAL CAR T CELL THERAPY IN ACUTE LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
  • 4. GLOBAL CAR T CELL THERAPY IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
  • 5. GLOBAL CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
  • 6. GLOBAL CD19 TARGETED CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
  • 7. GLOBAL CD22 TARGETED CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
  • 8. GLOBAL OTHER TARGETED CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
  • 9. GLOBAL CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2022-2030($ MILLION)
  • 10. NORTH AMERICAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030($ MILLION)
  • 11. NORTH AMERICAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
  • 12. NORTH AMERICAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
  • 13. EUROPEAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030($ MILLION)
  • 14. EUROPEAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
  • 15. EUROPEAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
  • 16. ASIA-PACIFIC CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030($ MILLION)
  • 17. ASIA-PACIFIC CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
  • 18. ASIA-PACIFIC CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
  • 19. REST OF THE WORLD CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
  • 20. REST OF THE WORLD CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CAR T CELL THERAPY MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 2. GLOBAL CAR T CELL THERAPY MARKET SHARE BY TARGET ANTIGEN, 2022 VS 2030 (%)
  • 3. GLOBAL CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CAR T CELL THERAPY IN NON-HODGKIN LYMPHOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CAR T CELL THERAPY IN ACUTE LYMPHOCYTIC LEUKEMIA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CAR T CELL THERAPY IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CD19 TARGETED CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CD22 TARGETED CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHER TARGETED CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. US CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. CANADA CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. UK CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. FRANCE CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. GERMANY CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. ITALY CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. SPAIN CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. ROE CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. INDIA CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CHINA CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. JAPAN CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF ASIA-PACIFIC CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF THE WORLD CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)